EGFR and colonic neoplasm: Our results indicated IRSp53 upregulation in patients suffering colon cancer and reduction of EGFR/c-Src/IRSp53/p-AKT/p-Stat3/cyclin D1 signaling pathway, which led to suppression of cell proliferation in the hAMSCs-treated HT-29 colon cancerous cells.